Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
511 results about "Immune disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An immune disorder is a dysfunction of the immune system. These disorders can be characterized in several different ways...
Method for detection and quantification of T-cell receptor Vbeta repertoire
ActiveUS20070117134A1Enhances PCR reaction sensitivityRapid determinationAnalysis using chemical indicatorsSugar derivativesVaccinationAntigen stimulation
The invention is a method for detecting and measuring T-cell receptor (TCR) repertoires from mammalian lymphocytes. The method is based on the use of the multiple sets of unique primers to amplify 22 regions of the TCR Vβ region and thereby detect clonal expansions related to antigen stimulation of the immune system. Kits containing sets of primers and specialized analytical statistical software for use in determining clonal expansion in humans and mice are disclosed. The reliability, efficiency and short assay time in using the method is well suited to monitoring immune response to vaccination and therapeutic treatments for immune disorders.
Owner:SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ActiveUS7662387B2Prevent relapseAntibacterial agentsNervous disorderImmunosuppressive drugCytotoxicity
Owner:SEAGEN INC
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ActiveUS20060233794A1Prevent relapseAntibacterial agentsNervous disorderDrug conjugationAntiendomysial antibodies
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
Owner:SEAGEN INC
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
The present invention relates to methods and compositions for the treatment of CD20-expressing cancers and immune disorders involving CD20-expressing cells. The present methods comprise administering to a subject an anti CD20 antibody-drug conjugate that has a high potency and / or is capable of internalizing into CD20-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention yet further provides methods of and compositions relating to combination therapy of cancer and immune disorders involving CD20-expressing cells using the anti-CD20 antibody-drug conjugates of the invention.
Owner:SEATTLE GENETICS INC
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
Owner:SEAGEN INC
Compounds for inflammation and immune-related uses
InactiveUS20060173006A1Inhibit inflammationInhibit productionBiocideSenses disorderStructural formulaMedicinal chemistry
The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, R3, R18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Owner:SYNTA PHARMA CORP
Compositions and methods for the treatment and diagnosis of immune disorders
InactiveUS6084083AReduce in quantityLower Level RequirementsAntibacterial agentsBacteriaClinical trialCell subpopulations
Owner:MILLENNIUM PHARMA INC
Synbiotic Composition For Infants
InactiveUS20070207132A1Improve the level ofOrganic active ingredientsBiocidePhysiologyBifidobacterium breve
There is provided a preparation comprising Bifidobacterium breve and a mixture of non-digestible carbohydrates for non- or partially breast-fed infants as well as the use thereof for the treatment or prevention of immune disorder in non- or partially breast-fed infants. Also provided herein are sequence primers and probe for the detection of Bifidobacterium species as well as diagnostic kit thereof.
Owner:NUTRICIA
Nucleic acid molecules encoding a 103 gene product and uses therefor
InactiveUS6323334B1Decrease in production levelReduce in quantityBacteriaPeptide/protein ingredientsAntigenNucleotide
The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention provides a nucleotide sequence which encodes a previously unknown human 103 gene product. The invention also provides expression vectors containing the nucleic acid molecules of the invention and host cells into which the expression vectors have been introduced. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies.
Owner:MILLENNIUM PHARMA INC
Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
InactiveUS20030068320A1Symptoms improvedGood curative effectAntipyreticAnalgesicsSide effectAutoimmune disease
The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes.
Owner:MEDIMMUNE LLC
Tec family kinase inhibitor adjuvant therapy
Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
Owner:PHARMACYCLICS
Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
The invention relates to compounds of structural formula (I) or (III): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein ring A, X1, X2, X3, X5, R1, R4, Y, Z, L, m and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Owner:SYNTA PHARMA CORP
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
InactiveUS20080025989A1Prevent relapseCompounds screening/testingAntibody ingredientsCytotoxicityAnti-CEA Antibody
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
Owner:SEATTLE GENETICS INC
Vinyl-phenyl derivatives for inflammation and immune-related uses
The invention relates to compounds of structural formula (Ia): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, X4, X6, X10, R1, Y, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Owner:SYNTA PHARMA CORP
Method for detection and quantification of T-cell receptor Vbeta repertoire
ActiveUS7375211B2Rapid determinationEasily detecting clonalityAnalysis using chemical indicatorsSugar derivativesVaccinationAntigen stimulation
The invention is a method for detecting and measuring T-cell receptor (TCR) repertoires from mammalian lymphocytes. The method is based on the use of the multiple sets of unique primers to amplify 22 regions of the TCR Vβ region and thereby detect clonal expansions related to antigen stimulation of the immune system. Kits containing sets of primers and specialized analytical statistical software for use in determining clonal expansion in humans and mice are disclosed. The reliability, efficiency and short assay time in using the method is well suited to monitoring immune response to vaccination and therapeutic treatments for immune disorders.
Owner:SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD
Substituted biaryl compounds for inflammation and immune-related uses
InactiveUS20070254363A1Inhibit inflammationInhibit productionBiocideSenses disorderMedicineStructural formula
The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein A, Y, L, R1, W1 and W2 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Owner:SYNTA PHARMA CORP
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
Owner:SEAGEN INC
Compounds for inflammation and immune-related uses
The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.
Owner:SYNTA PHARMA CORP
Thiophene compounds for inflammation and immune-related uses
InactiveUS20060199845A1Prevent proliferationInhibiting cytokine productionBiocideSenses disorderPharmaceutical medicineMedicinal chemistry
The invention relates to compounds of structural formulas (I) and (XVI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, Z, L, L2, R1, R2, R3, R21, n, q, and t are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Owner:SYNTA PHARMA CORP
Pyridone and aza-pyridone compounds and methods of use
Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Owner:GENENTECH INC +1
Substituted aromatic compounds for inflammation and immune-related uses
The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, A, W1, W2, and R′1 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Owner:SYNTA PHARMA CORP
Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
The invention relates to compounds of formula (XVI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein Y2, Z, L1, R9, R10, m and u are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, immune disorders, and allergic disorders.
Owner:SYNTA PHARMA CORP
Method for treating inflammatory disorders
InactiveUS20100280032A1Reduce expressionReduce productionBiocideSenses disorderInflammatory disorderImmune disorder
The present invention relates to a method for suppressing the immune system in a subject in need thereof, and a method for treating an inflammatory or immune disorder in a subject in need thereof.
Owner:SYNTA PHARMA CORP
Compounds for inflammation and immune-related uses
InactiveUS20070249661A1Modulate activityInhibit cell proliferationBiocideSenses disorderMedicinal chemistryInflammation
The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.
Owner:SYNTA PHARMA CORP
Pyridylphenyl compounds for inflammation and immune-related uses
The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, X1, X2, Z, R3, R4, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Owner:SYNTA PHARMA CORP
CD16A Binding Proteins and Use for the Treatment of Immune Disorders
InactiveUS20080050371A1Good curative effectEffective treatmentHybrid immunoglobulinsAntipyreticThrombocytopenic purpuraImmunologic diseases
CD16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.
Owner:MACROGENICS INC
Multiplex determination of lipid specific binding moieties
InactiveUS20070020691A1Improve throughputPrevent and decrease autoimmune responseBioreactor/fermenter combinationsBiocideLipid formationAutoimmune condition
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Methods for the treatment of immune disorders
InactiveUS6066322ALow effective concentrationDecrease in levelAntibacterial agentsBacteriaClinical trialCell subpopulations
The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials.
Owner:MILLENNIUM PHARMA INC
Markers associated with the therapeutic efficacy of glatiramer acetate
The present invention is directed to methods and kits based, at least in part, on the identification of allele-specific responsiveness or non-responsiveness to glatiramer acetate for the treatment of immune disorders, such as relapsing-remitting multiple sclerosis. The allele-specific responsiveness or non-responsiveness is based on polymorphisms in the following genes, CTSS, MBP, TCRB, CD95, CD86, IL-1R1, CD80, SCYA5, MMP9, MOG, SPP1 and IL-12RB2.
Owner:RAPPAPORT FAMILY INSTITUTE FOR RESEACH IN THE MEDICAL SCIENCES +2
Compounds for inflammation and immune-related uses
The invention relates to compounds of structural formula (I) and structural formula (VI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R, R1, R2, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Owner:PRCL RES INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com